Contact Us

The choice depends on whether you are studying SLC37A3's role as a putative phosphate/glucose-6-phosphate ER transporter or its emerging functions in lysosomal/ER compartment biology. The Knockout line is appropriate for asking whether SLC37A3 is required for these activities, though its substrate specificity is less defined than its SLC37A4 (G6PT) paralog. Overexpression is useful for testing transport activity in heterologous systems. For SLC37 family research, the EDITGENE Knockout in HEK293 provides a clean background for biochemical and functional studies. SLC37A3 has been reported to participate in lysosomal compartment biology in some contexts. Rescue with wild-type SLC37A3 enables initial functional characterization and substrate scope studies.

Yes. SLC37A3 rescue experiments require attention to MFS family architecture: • Construct design: use a codon-modified SLC37A3 sequence with a small C-terminal tag (FLAG, HA). The predicted MFS transporter architecture should be preserved. • Localization validation: confirm subcellular localization (ER, lysosomal, or plasma membrane) by appropriate compartment marker co-staining. • Transport-deficient rescue: conserved MFS family residue mutations enable structure-function studies. • Functional readout: rescue should restore phenotypes identified during knockout phenotype characterization; substrate-specific transport assays test predicted activities. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC35B3's role as a Golgi PAPS (3'-phosphoadenosine 5'-phosphosulfate) transporter or its contributions to sulfated proteoglycan biosynthesis. The Knockout line is appropriate for asking whether SLC35B3 is required for sulfation of glycosaminoglycans and other secreted/membrane sulfated molecules. Overexpression is useful for testing PAPS transport activity in heterologous systems. For glycosaminoglycan sulfation research, the EDITGENE SLC35B3 Knockout in HEK293 is a mechanistic platform — sulfation is essential for the biological activity of heparan sulfate, chondroitin sulfate, and other sulfated GAGs. SLC35B2 paralog expression should be assessed given functional overlap in PAPS delivery to the Golgi. Rescue with wild-type or transport-deficient SLC35B3 enables structure-function studies.

Yes. SLC35B3 rescue experiments require attention to Golgi targeting and PAPS transport mechanism: • Construct design: use a codon-modified SLC35B3 sequence with a small C-terminal tag (FLAG, HA). Preserve transmembrane topology and Golgi targeting determinants. • Golgi localization validation: confirm Golgi localization by GM130 co-staining before functional assays. • Transport-deficient rescue: conserved residue mutations in PAPS-binding sites enable structure-function studies. • Functional readout: rescue should restore Golgi PAPS uptake (in vitro membrane assays) and downstream sulfation of GAGs and sulfated glycoproteins. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC2A12 (GLUT12)'s role as a class III facilitative glucose transporter or its functions in insulin-responsive glucose uptake in non-classical contexts. The Knockout line is the standard tool for asking whether GLUT12 is required for glucose uptake — GLUT12 is principally expressed in cardiac and skeletal muscle, adipose tissue, prostate, and small intestine, and has been characterized as an insulin-responsive glucose transporter, distinct from but complementary to GLUT4. Overexpression is useful for testing transport activity in heterologous systems or for studying GLUT12 trafficking dynamics. For GLUT12 research, the EDITGENE Knockout in HEK293 is a standard mechanistic platform — HEK293 has been extensively used for GLUT family biochemistry and structure-function characterization. Note that physiological insulin-responsive GLUT12 trafficking research benefits from muscle (L6, C2C12) or adipocyte (3T3-L1) models. GLUT12 has emerging relevance in prostate cancer where it has been reported as upregulated and contributing to glucose handling in tumor cells. Rescue with wild-type or transport-deficient GLUT12 is the standard specificity control.

Yes. GLUT12 rescue experiments require attention to its dual intracellular/surface trafficking biology: • Construct design: use a codon-modified SLC2A12 sequence with a small C-terminal tag (FLAG, HA). GLUT12 has 12 transmembrane domains in the canonical GLUT family architecture — both N- and C-terminal cytoplasmic tags are tolerated, though small epitope tags are preferred over large fusions. • Trafficking-mutant rescue: GLUT12 contains dileucine-based and tyrosine-based sorting motifs in its N-terminal cytoplasmic region — specific mutations in these motifs disrupt intracellular retention and enable trafficking mechanism studies. • Transport-deficient rescue: substrate-binding pocket mutations (analogous to GLUT4 transport-deficient mutations) enable structure-function studies separating transport activity from trafficking functions. • Functional readout: rescue should restore ³H-2-deoxyglucose uptake activity; for trafficking studies, surface biotinylation or imaging-based quantification of plasma membrane GLUT12 pools. HEK293 transduces efficiently with lentivirus and is well-suited for GLUT12 biochemistry and trafficking studies in a heterologous expression context.

The choice depends on whether you are studying SLC25A30 (KMCP1, kidney mitochondrial carrier protein 1)'s role as a mitochondrial inner membrane carrier or its emerging functions in mitochondrial energetics. The Knockout line is appropriate for asking whether SLC25A30 is required for the predicted carrier activities — SLC25A30 has homology to uncoupling proteins but its specific substrate has not been fully characterized. Overexpression is useful for substrate identification through reconstituted transport assays. For SLC25 family research, the EDITGENE SLC25A30 Knockout in HEK293 provides a clean genetic background for characterizing this carrier's substrate scope and cellular function. Mitochondrial bioenergetics assays (Seahorse, membrane potential) in the knockout can identify functional consequences. Rescue with wild-type SLC25A30 enables initial functional characterization.

Yes, and rescue experiments are particularly important for substrate identification: • Construct design: use a codon-modified SLC25A30 sequence with a small C-terminal tag (FLAG, HA). The canonical SLC25 family architecture should be preserved. • Mitochondrial localization validation: confirm mitochondrial inner membrane localization before functional assays. • Discovery-oriented rescue: parallel rescue with wild-type construct during phenotypic characterization helps distinguish SLC25A30-dependent phenotypes. • Functional readout: rescue should restore phenotypes identified during knockout characterization (mitochondrial bioenergetics, candidate substrate transport). HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC30A6 (ZnT6)'s role in Golgi zinc transport or its emerging functions in zinc compartmentalization. The Knockout line is appropriate for asking whether ZnT6 is required for delivering zinc to the Golgi/trans-Golgi network — ZnT6 has been reported to form heterodimers with ZnT5 (SLC30A5) for functional zinc efflux from the cytoplasm. Overexpression is useful for studying ZnT5/ZnT6 heterodimer biology or for testing zinc compartmentalization. For ZnT family research, the EDITGENE Knockout in HEK293 is a mechanistic platform. ZnT5 expression should be characterized in parallel given the heterodimer dependency for ZnT6 function. Rescue with wild-type or transport-deficient ZnT6, with confirmation of ZnT5 expression, enables structure-function studies.

Yes. ZnT6 rescue experiments require attention to ZnT5 heterodimer partnership: • Construct design: use a codon-modified SLC30A6 sequence with a small C-terminal tag (FLAG, HA). ZnT6 has 6 transmembrane domains in the canonical ZnT family architecture. • ZnT5 co-expression: ZnT6 forms functional heterodimers with ZnT5 — rescue interpretation should account for ZnT5 expression in HEK293, or co-rescue may be needed in ZnT5-low backgrounds. • Golgi localization validation: confirm Golgi targeting of exogenous ZnT6 by GM130 co-staining. • Functional readout: rescue should restore Golgi zinc levels and zinc-dependent secretory enzyme activities (e.g., alkaline phosphatase). HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on the experimental question. SLC35A5 belongs to the SLC35 nucleotide sugar transporter family, but its substrate specificity and cellular function are less well characterized than SLC35A1-A4. The Knockout line is most useful for discovery-oriented studies to identify cellular processes requiring SLC35A5 — given the family's role in delivering nucleotide sugars (UDP-GlcNAc, GDP-fucose, etc.) for glycoprotein and glycolipid biosynthesis. Overexpression is useful for substrate identification through reconstituted transport assays. For SLC35 family research, the EDITGENE SLC35A5 Knockout in HEK293 provides a clean background for characterizing this transporter's substrate scope. Glycomic profiling and lectin staining in the knockout can identify candidate substrate classes. Rescue with wild-type SLC35A5 enables initial functional characterization.

Yes, and rescue experiments are particularly important for substrate discovery: • Construct design: use a codon-modified SLC35A5 sequence with a small C-terminal tag (FLAG, HA). The 10 transmembrane SLC35 family architecture should be preserved. • Discovery-oriented rescue: parallel rescue with wild-type construct during glycomic profiling distinguishes true SLC35A5-dependent glycan changes from off-target editing artifacts. • Localization validation: confirm Golgi localization by GM130 co-staining before functional analyses. • Functional readout: rescue should restore glycomic profiles or specific glycan structures identified during knockout characterization. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC7A5 (LAT1)'s role in mTORC1-regulating leucine transport or its emerging functions in cancer biology and drug delivery. The Knockout line is the standard tool for asking whether LAT1 is required for large neutral amino acid (leucine, isoleucine, valine, methionine, phenylalanine) uptake — LAT1 is upregulated in many cancers and is a target for both PET imaging (¹⁸F-FDOPA) and therapeutics. Overexpression is useful for testing transport activity (requires 4F2hc partnership) or for studying LAT1 in cancer contexts where it is amplified. For LAT1 research, the EDITGENE Knockout in HeLa is a well-characterized cancer cell line for studying amino acid transporter biology and mTORC1 nutrient signaling. Rescue with wild-type or transport-deficient LAT1 enables structure-function studies, and is particularly valuable as a specificity control for LAT1 inhibitors (JPH203/nanvuranlat, others) in clinical development.

Yes. LAT1 rescue experiments are well-established in transporter pharmacology research: • Construct design: use a codon-modified SLC7A5 sequence with a small C-terminal tag (FLAG, HA). The 12 transmembrane topology must be preserved. • 4F2hc partnership: LAT1 requires 4F2hc for functional surface expression — HeLa expresses 4F2hc endogenously, but high-level LAT1 rescue may require 4F2hc co-expression for stoichiometric balance. • Transport-deficient rescue: substrate-binding mutations or established inhibitor-binding residue mutations enable structure-function studies. • Functional readout: rescue should restore large neutral amino acid uptake (³H-leucine) and downstream mTORC1 activation under amino acid challenge. HeLa transduces efficiently with lentivirus and is well-validated for LAT1 functional studies.

The choice depends on whether you are studying SLC8B1 (NCLX, mitochondrial Na+/Ca2+ exchanger)'s role in mitochondrial calcium efflux or its emerging functions in cancer metabolism and cell death regulation. The Knockout line is appropriate for asking whether NCLX is required for mitochondrial calcium extrusion — particularly relevant in colorectal cancer contexts where mitochondrial calcium dynamics affect bioenergetics and apoptosis sensitivity. Overexpression is useful for testing whether enhanced NCLX activity protects against calcium-induced mitochondrial dysfunction. For mitochondrial calcium research, the EDITGENE SLC8B1 Knockout in HCT 116 enables study of NCLX-MCU coupling — NCLX provides the dominant calcium efflux pathway counteracting MCU-mediated calcium uptake. Rescue with wild-type or transport-deficient NCLX enables mechanistic dissection of mitochondrial calcium homeostasis. NCLX inhibitors (CGP-37157) are research tools; the knockout serves as a genetic specificity control.